Libertas Funding, a technology-enabled specialty finance company that provides funding solutions to small and medium-sized businesses, entered into a warehouse financing agreement of up to $100 million with Silicon Valley Bank.
Impel NeuroPharma, a late-stage biopharmaceutical company, closed a $50 million debt facility with Oxford Finance and Silicon Valley Bank. The first $20 million of the facility was funded at closing.
SVB Financial Group, the parent of Silicon Valley Bank, completed the acquisition of Boston Private Financial Holdings, the parent company of Boston Private Bank & Trust.
PLAYSTUDIOS, a developer of free-to-play casual mobile and social games, entered into a $75 million, five-year secured revolving credit facility to support its future growth initiatives. JPMorgan Chase served as the administrative agent for the transaction.
INmune Bio, a clinical-stage immunology company focused on developing treatments that harness patients’ innate immune systems to fight disease, entered into a new $15 million credit facility with Silicon Valley Bank and an affiliate of SVB Financial Group.
VidCrunch secured a multi-million-dollar financing facility from Silicon Valley Bank to its global sales team, enhance its engineering resources and continue its ongoing investments in product development, content curation and creation for its publisher portfolio.
Akili Interactive, the maker of EndeavorRx, a prescription video game treatment, secured $160 million in combined equity and debt financing, including a credit facility of up to $50 million with Silicon Valley Bank.
Silicon Valley Bank appointed Christopher Hollins head of product sales. In this role, he will lead SVB’s product sales and implementation teams, which provide foreign exchange, treasury and global payments solutions to SVB clients.
SCYNEXIS secured a $60 million term loan facility with Hercules Capital and Silicon Valley Bank. The capital strengthens SCYNEXIS’ balance sheet ahead of the anticipated commercial launch of Brexafemme, an oral antifungal product for the treatment of vaginal yeast infections.
Eyenovia, a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose array print therapeutics, entered into a new $25 million credit financing facility with Silicon Valley Bank.